• Medical Professionals
    • Information for Healthcare Providers
    • Clinical Studies
    • Expanded Access
    • Educational Grants
    • Request Information
  • Press releases
  • Suppliers
  • Contact
  • Skip to main content
  • Skip to footer

Atara Biotherapeutics

  • About
    • Company
    • Management Team
    • Board of Directors
    • Collaborators
    • Contact
  • Technology
  • Pipeline
    • Atara Pipeline
    • Tab-cel
    • ATA188
    • ATA2271/ATA3271
    • ATA3219
  • Patients
    • Mission to Serve Patients
    • Clinical Studies
    • Expanded Access
    • Request Information
    • PTLD Champions
    • Multiple Sclerosis
  • Investors & Media
    • Investors & Media
    • News & Events
    • Financial Results
    • ATRA Stock
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Careers
    • Join Our Team
    • Life at Atara
    • Explore Career Opportunities
    • Tech Ops
    • Job Search
  • Medical Professionals
  • Suppliers
  • Press Releases
  • Contact
  • LinkedIn
  • Twitter
Investors & Media

Investors & Media

  • Investors & Media
  • News & Events
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Email Alerts
    • Investor & Media Contacts
  • Financial Results
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • ATRA Stock
    • Quote
    • Charts
    • Historical Data
    • FAQ
    • Classification Info
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Contact The Board
  • News
  • Careers

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • Events
  • Presentations
  • Email Alerts
  • Investor & Media Contacts

Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies

Sep 06, 2018 7:30am EDT

Atara Biotherapeutics to Participate at Two Upcoming Conferences

Aug 31, 2018 8:00am EDT

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 06, 2018 4:50pm EDT

Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress

Aug 01, 2018 8:00am EDT

Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference

Jul 31, 2018 4:45pm EDT

Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline

Jun 25, 2018 8:00am EDT

Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas

Jun 15, 2018 2:30am EDT

Atara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus (EBV) Infection and Multiple Sclerosis (MS)

Jun 13, 2018 8:00am EDT

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 07, 2018 5:20pm EDT

Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer

Jun 07, 2018 8:00am EDT
RSS
  • Prev
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...23
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed

    Footer

    • LinkedIn linkedin
    • Twitter twitter
    © 2021 Atara Biotherapeutics, Inc. All Rights Reserved
    • Privacy Policy
    • Sitemap

    This website uses cookies and similar technologies to optimise and improve the experience on our site. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy


    OK